SALTO: A randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction

Bulletin du Cancer

Volumn 99, Issue 2, 2012, Pages

  Laval, Guillemette ^a   Rousselot, Hubert ^b   Toussaint Martel, Sophie ^b   Mayer, Françoise ^c   Terrebonne, Éric ^d   François, Éric ^e   Brixi, Hédia ^f   Nguyen, Thierry ^g   Bourdeix, Isabelle ^h   Bisot Locard, Ségolène ^h   Zelek, Laurent ⁱ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h NOVARTIS PHARMA K K   (Japan)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

Bowel obstruction; Cancer; End stage cancer patients; Octreotide LAR

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LAXATIVE; METHYLPREDNISOLONE; MORPHINE; OCTREOTIDE; PLACEBO; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; SPASMOLYTIC AGENT; STOMACH SECRETION INHIBITOR;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERGLYCEMIA; IMMEDIATE RELEASE FORMULATION; INFLAMMATION; INJECTION SITE ERYTHEMA; INOPERABLE CANCER; INTESTINE OBSTRUCTION; KARNOFSKY PERFORMANCE STATUS; LONG ACTING REPEATABLE FORMULATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT INTESTINE OBSTRUCTION; MULTICENTER STUDY; NASOGASTRIC TUBE; PARENTERAL NUTRITION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 84856889776     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1535     Document Type: Article

References (21)

1. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer 2008; 48 : 1105-15.
2. Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N. Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manage 2006; 31 : 502-12. (Pubitemid 44192410)
3. Helyer L, Easson AM. Surgical approaches to malignant bowel obstruction. J Support Oncol 2008; 6 : 105-13. (Pubitemid 351459976)
4. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88 : 358-63. (Pubitemid 30051820)
5. Laval G, Beziaud N, Villard ML. Symptomatic treatments (pain management excluded) for adults in palliative care. Rev Prat 2009; 59 : 785-97.
6. Laval G, Girardier J, Lassauniere JM, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?. Palliat Med 2000; 14 : 3-10. (Pubitemid 30095220)
7. Ripamonti C, Mercadante S. How to use octreotide for malignant bowel obstruction. J Support Oncol 2004; 2 : 357-64. (Pubitemid 39409784)
8. Murphy E, Prommer EE, Mihalyo M, Wilcock A. Octreotide. J Pain Symptom Manage 2010; 40 : 142-8.
9. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000; 19 : 23-34. (Pubitemid 30067620)
10. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8 : 188-91. (Pubitemid 30183034)
11. Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 2002; 22 : 1187-92. (Pubitemid 34836172)
12. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 7 : 295-9. (Pubitemid 23322784)
13. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996; 61 : 345-8. (Pubitemid 26170012)
14. Khoo D, Hall E, Motson R, Riley J, Denman K,Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30A : 28-30. (Pubitemid 24058083)
15. Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 2010; 40 : 739-45.
16. Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 2005; 30 : 563-9. (Pubitemid 41821208)
17. Myers J, Tamber A, Farhadian M. Management of treatmentrelated intermittent partial small bowel obstruction: the use of octreotide. J Pain Symptom Manage 2010; 39 : e1-3.
18. Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 2008; 38 : 354-9. (Pubitemid 351753567)
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10 : 1-10. (Pubitemid 19099520)
20. Mariani P, Blumberg J, Chauvenet L. Efficacy of lanreotide 30 mg as symptomatic treatment in patients with inoperable bowel obstruction due to peritoneal carcinomatosis: a randomized double-blind, placebo-controlled study 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29 (suppl. 4; abstract 242).
21. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage 2007; 34 : S49-59. (Pubitemid 46970817)